Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 1

Status

Active not recruiting 3Completed 2Recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 81Stomach Neoplasms 32Pancreatic Neoplasms 31Rectal Neoplasms 23Colonic Neoplasms 22Neoplasms 21Neoplasm Metastasis 19Esophageal Neoplasms 16Cholangiocarcinoma 13Carcinoma, Non-Small-Cell Lung 13Burkitt Lymphoma 13Adenocarcinoma Of Esophagus 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Biliary Tract Neoplasms 12Adenocarcinoma 11Ovarian Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Gastrointestinal Neoplasms 6Lung Neoplasms 5Leukemia, Biphenotypic, Acute 5Gallbladder Neoplasms 5Esophageal Squamous Cell Carcinoma 5Endometrial Neoplasms 5Carcinoma, Renal Cell 5Advanced Solid Tumors 5Triple Negative Breast Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Melanoma 4Leukemia 4

Interventions

pembrolizumab 119Cisplatin 33lenvatinib 29Carboplatin 28Paclitaxel 27Docetaxel 14Pemetrexed 13Fluorouracil 12Capecitabine 11Saline Solution 10Oxaliplatin 10Gemcitabine 10Albumin-Bound Paclitaxel 7olaparib 6Leucovorin 6Bevacizumab 6epacadostat 5belzutifan 5Etoposide 5Cetuximab 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enzalutamide 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3Radiotherapy 3Levoleucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Leucovorin × 1 year × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05239741 2026-05-22

MK-3475-C66

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
100 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03221426 2026-03-09

KEYNOTE-585

Merck Sharp & Dohme LLC

Phase 3 Completed
1,007 enrolled 25 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

Merck Sharp & Dohme LLC

Phase 3 Completed
120 enrolled 17 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡